IRADIMED CEO’s trust sells 7,500 IRADIMED (IRMD) shares under Rule 10b5-1 plan
Roger E. Susi, CEO of IRADIMED CORP, through the Phillip Susi 2008 Dynasty Trust, sold 7,500 shares of common stock between May 18-19, 2026, at prices ranging from $85.95 to $88.65 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025. Despite these sales, the trust retains a significant indirect stake in IRADIMED, and Susi disclaims beneficial ownership beyond his pecuniary interest.
Iradimed CEO Roger Susi sells $657,264 in company stock
Iradimed CEO Roger Susi indirectly sold 7,500 shares of IRADIMED CORP (NASDAQ:IRMD) stock, valued at $657,264, through a Rule 10b5-1 trading plan. These sales occurred on May 18 and May 19, 2026, after the stock experienced a significant 66% return over the past year. Despite recent strong Q1 2026 earnings that exceeded analyst expectations, the stock saw a pre-market decline, signaling investor concerns.
IRADIMED CEO and CFO head to Goldman Sachs health conference in Miami
IRADIMED Corporation announced that its President and CEO, Roger Susi, and CFO, Jack Glenn, will attend the Goldman Sachs 47th Annual Global Healthcare Conference from June 8–10, 2026, in Miami Beach. Interested investors can arrange one-on-one meetings with the management team through their Goldman Sachs representative. This participation is part of IRADIMED's ongoing efforts to engage with investors and highlight its MRI-compatible medical device business after strong financial results.
Iradimed (NASDAQ: IRMD) family trusts disclose 4.45M shares, 34.8% ownership
An amended Schedule 13G/A filing reveals that Roger E. Susi and related family trusts beneficially own 4,450,450 shares, representing 34.8% of Iradimed Corporation's common stock as of April 30, 2026. This aggregate ownership includes shares held by a revocable trust and two dynasty trusts, with specific allocations of sole and shared voting and dispositive powers among family members. The disclosure provides transparency on a significant minority stake and influential voting power within the company.
IRADIMED (IRMD) CEO Susi’s trust sells 7,500 pre-planned shares
IRADIMED's CEO Roger E. Susi, through the Phillip Susi 2008 Dynasty Trust, sold 7,500 shares of IRMD common stock on May 11 and May 12, 2026. These pre-planned sales, executed under a Rule 10b5-1 trading plan adopted in November 2025, occurred at weighted-average prices in the mid-$80s per share. The filing also notes indirect holdings by other trusts associated with Susi.
The Bull Case For IRADIMED (IRMD) Could Change Following Q1 Results And Reaffirmed 2026 Guidance - Learn Why
IRADIMED (IRMD) recently reported strong Q1 results with sales of US$21.98 million and net income of US$5.82 million, alongside reconfirming its full-year 2026 revenue and GAAP diluted EPS guidance. The company also declared a regular quarterly dividend. This update supports the investment case for IRADIMED, particularly regarding the adoption of its 3870 pump, while concentrating on MRI-compatible pumps remains a key factor to consider.
Iradimed CEO Roger Susi sells $642,861 in company stock
Iradimed CEO Roger Susi sold 7,500 shares of company stock for over $642,000 across May 4 and 5, 2026, under a pre-arranged trading plan. Despite the insider sale, the company recently reported strong first-quarter 2026 earnings, surpassing analyst expectations for both EPS and revenue. Mr. Susi still indirectly holds millions of shares through various trusts.
IRADIMED (IRMD) CEO-linked trust sells 7,500 shares under 10b5-1 plan
IRADIMED CORP CEO Roger E. Susi's family trust sold 7,500 shares of common stock on May 4-5, 2026, for proceeds totaling $642,862. These transactions were pre-scheduled under a Rule 10b5-1 trading plan adopted on November 5, 2025. Susi disclaims beneficial ownership beyond his pecuniary interest.
A Look At IRADIMED (IRMD) Valuation After Q1 2026 Growth, New Pump Rollout And Dividend
IRADIMED (IRMD) reported double-digit revenue and earnings growth for Q1 2026, reaffirmed its full-year guidance, and declared a dividend, along with rolling out its new 3870 MRI infusion pump. While long-term shareholder returns have been strong, short-term momentum has cooled. The company's valuation is mixed, with some metrics suggesting undervaluation at $118.67 fair value due to the new pump's expected market impact, while earnings multiples indicate the stock is significantly overvalued compared to its estimated fair ratio and industry peers.
IRadimed Corporation (NASDAQ:IRMD) Q1 2026 Earnings Call Transcript
IRadimed Corporation reported a strong first quarter for 2026, exceeding earnings expectations with a 13% revenue increase and 33% operating income improvement compared to Q1 2025. The company highlighted the successful product launch of its new 3870 MRI IV pump, noting higher-than-anticipated average selling prices and a surprising number of customers opting for Quad (four-channel) systems, which is driving significant growth in bookings and future revenue. IRadimed reaffirmed its full-year 2026 guidance and declared a quarterly cash dividend, with optimism surrounding the replacement opportunity for its existing installed base of older pump systems.
Is IRADIMED’s 3870 Pump Launch And Reaffirmed Outlook Altering The Investment Case For IRMD?
IRADIMED Corporation (IRMD) recently reported strong Q1 2026 results, including increased sales and net income, alongside the launch of its new 3870 MRI-compatible IV infusion pump. The company reaffirmed its full-year 2026 revenue and EPS guidance, reinforcing the investment narrative around its niche market and the new pump's replacement cycle. While the strong demand for the 3870 pump supports growth, execution risks related to production ramp-up and backlog conversion remain key short-term factors.
IRADIMED (IRMD) Revenue Growth Track Tests Bullish MRI Demand Narratives
IRADIMED (IRMD) is showing consistent profitability with revenue growth, but its stock valuation raises concerns. While revenue and earnings have been strong, the forecast growth rates are slower than historical performance and market expectations. The company's high P/E ratio and valuation gap compared to its DCF fair value highlight potential risks, especially given its reliance on a narrow product range.
iRadimed Corporation (NASDAQ:IRMD) Plans Quarterly Dividend of $0.20
iRadimed Corporation (NASDAQ:IRMD) has announced a quarterly dividend of $0.20 per share, payable on May 29th to shareholders of record by May 15th. This dividend implies a 0.9% yield and a payout ratio of 40.2%, which is well-covered by current earnings. The announcement follows strong Q1 results, where the company surpassed EPS and revenue expectations and provided positive full-year guidance, despite some near-term execution risk due to slightly cautious Q2 revenue guidance.
IRADIMED CORP 1Q 2026: Revenue $21.98M, EPS $0.45— 10-Q Summary
IRADIMED CORP reported its first-quarter 2026 financial results, with revenue reaching $21.98 million and diluted EPS at $0.45, showing an increase compared to the previous year. The growth was primarily driven by higher device sales and improved operating performance, particularly from MRidium IV pump systems and 3880 vital signs monitors. The company also increased its R&D investment for the MRidium 3870 development and improved operating cash flows.
IRADIMED (NASDAQ: IRMD) Q1 2026 revenue rises 13% to $22M
IRADIMED Corporation reported a strong first quarter for 2026, with revenue increasing by 13% to $22.0 million and net income rising to $5.82 million. This growth was primarily fueled by robust sales of MRI-compatible IV infusion pumps and patient monitoring systems, alongside higher amortization from extended maintenance agreements. The company maintained a high gross margin of 77% and declared a quarterly dividend of $0.20 per share, demonstrating solid financial health and commitment to shareholder returns.
IRadimed: Q1 Earnings Snapshot
IRadimed Corp. (IRMD) reported a net income of $5.8 million, or 45 cents per share, for its first quarter, with adjusted earnings of 49 cents per share. The company, which manufactures IV devices for MRI machines, recorded $22 million in revenue for the period. IRadimed provided forward-looking guidance, expecting second-quarter earnings between 44 and 48 cents per share on revenues of $20 million to $21 million, and full-year earnings of $2.06 to $2.21 per share with revenue between $91 million and $96 million.
IRADIMED (NASDAQ: IRMD) Q1 growth, dividend and 2026 outlook
IRADIMED (NASDAQ: IRMD) reported strong first-quarter 2026 results with a 13% revenue increase to $22.0 million and a 22% rise in GAAP diluted EPS to $0.45. The company launched its next-generation 3870 MRI-compatible IV infusion pump and declared a quarterly cash dividend of $0.20 per share. Management also reaffirmed its full-year 2026 revenue guidance of $91.0–$96.0 million and GAAP diluted EPS of $1.90–$2.05, signaling confidence in future growth.
MRI device maker IRADIMED launches new pump as Q1 sales climb 13%
IRADIMED (NASDAQ: IRMD) reported strong first-quarter 2026 financial results, with revenue increasing 13% year-over-year to $22.0 million and record GAAP diluted EPS of $0.45. The company also announced the commercial launch of its next-generation 3870 MRI-compatible IV infusion pump, which has received encouraging customer reception and strong early orders. IRADIMED reaffirmed its full-year 2026 guidance and declared a quarterly cash dividend of $0.20 per share.
Executive pay and director votes at Iradimed (NASDAQ: IRMD) 2026 meeting
Iradimed (NASDAQ: IRMD) will hold its 2026 annual meeting on June 23, 2026, in Orlando, where stockholders will vote on the election of five directors, auditor ratification, and a non-binding "say-on-pay" resolution for 2025 executive compensation. In 2025, the company reported $83.8 million in gross revenue and $22.5 million in net income, with CEO Roger Susi's total compensation at $780,598. Susi, who is also a founder, beneficially owns approximately 34.6% of the company's outstanding common shares.
Iradimed CEO Susi’s trust sells $657,709 in company stock
Roger E. Susi, CEO of IRADIMED CORP, indirectly sold 7,500 shares of company stock worth $657,709 through the Phillip Susi 2008 Dynasty Trust. These transactions, conducted under a Rule 10b5-1 trading plan, occurred on April 27 and April 28, 2026, with shares priced between $84.13 and $89.70. Despite the company's strong past year performance and recent positive financial results, InvestingPro analysis suggests the stock is overvalued.
IRADIMED (IRMD) CEO-linked trust sells 7,500 shares under 10b5-1 plan
A trust linked to Roger E. Susi, CEO, President, and Chairman of IRADIMED (IRMD), sold 7,500 shares of common stock on April 27-28, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. The sales were executed in several transactions at weighted average prices between approximately $84 and $90 per share. Following these transactions, the Phillip Susi 2008 Dynasty Trust indirectly holds 2,197,905 shares, with additional indirect holdings reported by other trusts associated with Susi.
iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
iRadimed (IRMD) reported Q1 earnings of $0.49 per share, exceeding the Zacks Consensus Estimate of $0.45, and revenues of $21.98 million, also surpassing estimates by 1.61%. The company has consistently beaten EPS estimates in three of the last four quarters and revenue estimates in three of the last four quarters. Despite these positive results, iRadimed's stock has faced a 14.2% decline year-to-date, contrasting with the S&P 500's 5.3% gain.
IRADIMED to post Q1 results before the bell May 1, call at 11 a.m. ET
IRADIMED (NASDAQ: IRMD) will release its Q1 2026 financial results before market open on May 1, 2026, and will host a conference call on the same day at 11:00 a.m. ET to discuss the results and answer questions. Registration is required to receive dial-in details, and a live webcast will also be available with a recording posted afterward. This announcement follows IRADIMED's established pattern of pre-announcing quarterly results and hosting calls, which historically results in modest stock price reactions.
Iradimed Corp Stock Receives Strong Buy Ratings from Analysts
Iradimed Corp (NASDAQ: IRMD) has received "Buy" ratings from all three analysts covering the stock, with a median one-year target price suggesting a nearly 34% upside. This positive outlook is driven by the company's unique position as the sole provider of non-magnetic MRI-compatible IV infusion pumps and patient monitoring systems, along with its product growth and potential for international expansion. Freedom Broker initiated coverage with a Buy rating and a $116 price target, highlighting Iradimed's profitability and specialized product portfolio.
Here is Why Investors Should Pay Attention to IRADIMED Corp. (IRMD)
IRADIMED Corp. (NASDAQ: IRMD) is highlighted as an oversold small-cap stock with a strongly bullish consensus sentiment and significant upside potential, according to analysts. The company is noted for its unique non-magnetic MRI compatible IV infusion pump and patient monitoring solutions. Freedom Broker initiated coverage with a "Buy" rating, projecting a 30%+ upside, reinforcing the positive outlook based on the company's profitability and international expansion potential.
iRadimed Corporation $IRMD Shares Sold by Copeland Capital Management LLC
Copeland Capital Management LLC reduced its stake in iRadimed Corporation (NASDAQ:IRMD) by 4.8% in the fourth quarter, selling 20,950 shares. Despite this, institutional investors still own a significant 92.34% of the company, while corporate insiders have sold 50,000 shares in the past three months. iRadimed surpassed Q4 earnings estimates, provided strong Q1 and full-year 2026 guidance, and increased its quarterly dividend.
Roger Susi Sells 5,000 Shares of iRadimed (NASDAQ:IRMD) Stock
iRadimed CEO Roger Susi sold 5,000 shares of the company's stock for $93.36 per share on April 20, totaling $466,800, under a pre-arranged Rule 10b5-1 plan. Despite the sale, Susi still directly owns 2,205,000 shares, representing a minor reduction in his position. The company recently reported strong Q4 earnings, raised its quarterly dividend, and maintains an average "Buy" rating from analysts with a $120 price target.
Iradimed CEO Roger Susi sells $694k in common stock By Investing.com
Iradimed CEO Roger E. Susi recently sold common stock worth $694,124 across two days, April 20 and 21, 2026, through a Rule 10b5-1 trading plan adopted in November 2025. These transactions involved 7,500 shares from the Phillip Susi 2008 Dynasty Trust, occurring as IRMD shares have surged 74% over the past year and are considered overvalued. The company is set to report earnings soon, following a strong Q4 2025 performance and new "buy" rating from Freedom Broker with a $116 price target.
Iradimed CEO Roger Susi sells $694k in common stock
IRADIMED CORP (NASDAQ:IRMD) CEO Roger E. Susi, through the Phillip Susi 2008 Dynasty Trust, recently sold $694,124 worth of common stock on April 20 and 21, 2026. These transactions, executed under a Rule 10b5-1 trading plan, followed a 74% surge in IRMD shares over the past year, though the stock is currently considered overvalued. The company is set to report earnings on April 24, after a strong Q4 2025 performance and a new "buy" rating from Freedom Broker.
Iradimed CEO Roger Susi sells $694k in common stock
Iradimed CEO Roger Susi recently sold $694,124 worth of common stock through two transactions on April 20 and April 21, 2026. These sales, executed under a Rule 10b5-1 trading plan, involved 7,500 shares held indirectly by the Phillip Susi 2008 Dynasty Trust, with share prices ranging from $89.73 to $93.90. The stock sales occurred after IRMD shares surged 74% over the past year and just before the company is set to report earnings.
IRADIMED (IRMD) CEO-linked trust sells 7,500 shares under plan
The Phillip Susi 2008 Dynasty Trust, linked to IRADIMED CORP's CEO Roger E. Susi, sold 7,500 shares of common stock on April 20-21, 2026. These transactions, executed under a pre-scheduled Rule 10b5-1 trading plan adopted in November 2025, involved shares sold at prices ranging from $89.73 to $93.90. Despite the sales, the trust retains substantial indirect holdings, leading analysts to view this as routine portfolio management rather than a significant change in sentiment.
Tangible book value per share of IRadimed Corp. – LSX:A118V4
This article provides the tangible book value per share for IRadimed Corp. (LSX:A118V4). It is presented on a financial data platform, showing the period, value, and change for this financial metric. The content highlights a specific financial detail for investors interested in IRadimed Corp.
Insider Selling: iRadimed (NASDAQ:IRMD) CEO Sells 2,500 Shares of Stock
iRadimed (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of the company's stock on April 14th for $234,600, reducing his ownership by 0.11% as part of a pre-arranged trading plan. Despite this insider selling, the company has recently reported strong financial results, beating Q4 estimates and providing positive Q1 and FY2026 guidance. iRadimed also increased its quarterly dividend and maintains an average "Buy" rating from analysts with a consensus target price of $120.
Iradimed Insider Sold Shares Worth $697,189, According to a Recent SEC Filing
An insider at Iradimed Corporation (IRMD) sold shares valued at $697,189, as reported in a recent SEC filing. This transaction follows other insider sales by Iradimed personnel over the past month. Iradimed specializes in manufacturing MRI-compatible medical devices such as IV infusion pump systems and patient vital signs monitors.
Rule 10b5-1 sales by IRADIMED (IRMD) CEO-linked dynasty trust
IRADIMED director and CEO Roger E. Susi's family trust, the Phillip Susi 2008 Dynasty Trust, executed indirect open-market sales of 7,500 shares of IRADIMED common stock on April 13-14, 2026. These transactions were made under a Rule 10b5-1 trading plan adopted in November 2025, with shares sold at weighted average prices between $91 and $94. Following these sales, the Phillip Susi 2008 Dynasty Trust still holds 2,210,000 shares, while other related trusts also hold significant indirect shares.
Iradimed Corporation to Participate in 25th Annual Needham Virtual Healthcare Conference
Iradimed Corporation announced its participation in the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026, where CFO Jack Glenn will hold investor meetings. The company specializes in MRI-compatible medical devices, including its patented MRidium® IV infusion pump system and the Iradimed 3880 patient vital signs monitoring system, designed for safe operation during MRI procedures. This participation aims to enhance visibility and attract new investment for their innovative patient safety solutions.
IRADIMED's finance chief lines up investor meetings at Needham event
IRADIMED CORPORATION (NASDAQ: IRMD) announced that its CFO, Jack Glenn, will participate in the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026. Glenn will conduct one-on-one investor meetings to discuss corporate strategy and investor relations. The company has a history of positive investor responses to its updates, including recent record financials and increased dividends.
iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 5,000 Shares
iRadimed CEO Roger Susi recently sold 5,000 shares of the company's stock for $480,100, reducing his ownership by 0.22% to 2.22 million shares. This transaction occurred on April 6th under a pre-arranged Rule 10b5-1 plan. The company also reported strong Q4 results, surpassing analyst expectations, increased its quarterly dividend, and received a consensus "Buy" rating from analysts with an average target price of $120.00.
Roger Susi Sells 2,500 Shares of iRadimed (NASDAQ:IRMD) Stock
Roger Susi, CEO of iRadimed (NASDAQ:IRMD), sold 2,500 shares of the company stock on April 7th for $237,100 under a pre-arranged trading plan, reducing his position by 0.11%. Despite this sale and a 2.4% dip in stock price, iRadimed recently beat earnings expectations, provided strong Q1 and FY2026 guidance, and increased its quarterly dividend to $0.20 per share. Analysts maintain a "Buy" rating with an average price target of $120.00.
IRADIMED (IRMD) CEO-linked trusts sell 7,500 company shares in plan trades
IRADIMED CORP CEO Roger E. Susi's associated trusts, primarily the Phillip Susi 2008 Dynasty Trust, sold a total of 7,500 common stock shares in open-market transactions on April 6–7, 2026. The sales, executed under a pre-established Rule 10b5-1 trading plan, ranged in price from $94.36 to $96.78 per share. Following these transactions, the Phillip Susi 2008 Dynasty Trust now holds 2,217,500 shares, with Susi disclaiming beneficial ownership except for his pecuniary interest.
Does IRadimed’s New Bullish Analyst Coverage Reframe Its MRI Pump Story Or Just Test Sentiment (IRMD)?
Freedom Capital Markets analyst Ilya Zubkov initiated coverage on IRadimed (IRMD.US) with a buy rating, despite a modest prior-year success rate. This new coverage comes as IRadimed prepares for the rollout of its FDA-cleared MRidium 3870 IV Infusion Pump System, which is central to its growth forecast of $110.6 million revenue and $30.7 million earnings by 2029. However, the article highlights the concentration risk in MRI-compatible devices and the potential operational challenges with an extended pump backlog.
Freedom Broker initiates IRadimed stock coverage with buy rating
Freedom Broker has initiated coverage on IRadimed Corp (NASDAQ:IRMD) with a buy rating and a price target of $116.00, implying a potential upside of 20% from its current trading price of $96.53. The company, which operates profitably and pays dividends, specializes in non-magnetic MRI-compatible IV infusion pumps and patient monitoring systems, being the sole provider of both. This follows a strong Q4 2025 performance where IRadimed surpassed analyst expectations for both EPS and revenue.
Freedom Broker initiates IRadimed stock coverage with buy rating
Freedom Broker has initiated coverage on IRadimed Corp (NASDAQ:IRMD) with a buy rating and a price target of $116.00, suggesting a 20% potential upside from its current trading price of $96.53. The company, a medical technology firm specializing in non-magnetic MRI-compatible IV infusion pumps and patient monitoring systems, recently reported Q4 2025 earnings that exceeded analyst expectations. Despite trading at a high P/E ratio of 53.4, InvestingPro Tips rates IRadimed's financial health as "GREAT."
Iradimed CEO Susi sells $712k in shares
IRADIMED CORP CEO Roger E. Susi sold 7,400 shares of common stock for a total of $712,614 on March 30, 2026, through a pre-arranged trading plan. The sales occurred at varied prices between $94.36 and $97.16, with the stock trading near its 52-week high but considered overvalued by InvestingPro's fair value assessment. Despite the insider sale, Iradimed recently reported strong Q4 2025 financial results, surpassing analyst expectations for EPS and revenue.
Iradimed CEO Susi sells $712k in shares
Iradimed CEO Roger E. Susi sold 7,400 shares of the company's common stock for a total of $712,614 through a pre-arranged trading plan. These sales occurred on March 30, 2026, with prices ranging from $94.36 to $97.16 per share. Despite the sale, Susi retains significant indirect holdings in the company, which recently reported strong Q4 2025 financial results, exceeding analyst expectations.
Insider trust tied to IRADIMED (IRMD) CEO sells 7,500 shares under 10b5-1
A trust associated with IRADIMED CORP (IRMD) CEO Roger E. Susi, The Phillip Susi 2008 Dynasty Trust, sold 7,500 shares of common stock on March 30, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales occurred in three transactions at weighted average prices ranging from $94.81 to $96.53. After these sales, the Dynasty Trust still holds 2,225,000 shares, with additional indirect holdings reported in other trusts.
Iradimed Insider Sold Shares Worth $712,614, According to a Recent SEC Filing
An insider at Iradimed Corporation (NASDAQ: IRMD) sold shares valued at $712,614, as reported in a recent SEC filing. This transaction was published on April 1, 2026, at 3:45 PM EDT. Iradimed develops, manufactures, and distributes MRI-compatible medical devices such as IV infusion pump systems and patient vital signs monitoring systems.
CEO Of iRadimed Sold $752K In Stock
iRadimed's CEO, Roger E Susi, sold 7,500 shares of company stock worth $752,609 on March 25, as detailed in a recent SEC filing. The company (NASDAQ: IRMD) shows positive financial milestones, including 17.03% revenue growth and a high gross margin of 75.06%, but its EPS lags and its market capitalization is below industry averages. Insider transactions, while not primary investment drivers, offer valuable insights into a company's prospects.
Roger Susi Sells 2,500 Shares of iRadimed (NASDAQ:IRMD) Stock
iRadimed Corporation CEO Roger Susi sold 2,500 shares of the company's stock on March 24th for $250,700, reducing his ownership by 0.11% to 2,232,500 shares. The company recently exceeded Q4 earnings estimates, raised its Q1 and FY 2026 guidance, and increased its quarterly dividend. Analysts currently have a "Moderate Buy" rating on IRMD with an average price target of $120.
IRADIMED (NASDAQ: IRMD) CEO sells 7,500 trust-held shares under plan
IRADIMED CEO Roger E. Susi sold 7,500 shares of common stock indirectly through the Phillip Susi 2008 Dynasty Trust on March 23–24, 2026, at prices around $100 per share. These sales were pre-arranged under a Rule 10b5-1 trading plan adopted on November 5, 2025. Despite the sales, significant indirect holdings remain in various trusts, indicating routine portfolio management rather than opportunistic market timing.
